[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354369-105":59,"doc-detail-354369-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","implications-of-rho-gtpase-signaling-in-cancer-immunotherapy","Implications of Rho GTPase signaling in cancer immunotherapy","","Cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and CAR-T cell therapy, shows substantial clinical success yet leaves many patients with limited response due to tumor-intrinsic immune evasion and immune dysfunction in the tumor microenvironment (TME). Rho family small GTPases regulate cytoskeletal dynamics, trafficking, transcription, and metabolism. This review consolidates direct tumor-cell evidence and indirect immune-cell network effects, emphasizing recent mechanistic advances. It highlights knowledge gaps and proposes selective modulation of specific Rho GTPase pathways to improve immunotherapy efficiency.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/implications-of-rho-gtpase-signaling-in-cancer-immunotherapy/354369/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/implications-of-rho-gtpase-signaling-in-cancer-immunotherapy/354369.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do some patients fail to respond to cancer immunotherapy?","Question",{"text":112,"@type":113},"Response rates remain limited due to tumor-intrinsic immune evasion and immune cell dysfunction within the tumor microenvironment (TME).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do Rho family small GTPases play in cancer biology relevant to immunotherapy?",{"text":117,"@type":113},"Rho GTPases regulate cytoskeletal dynamics, intracellular trafficking, transcription, and metabolism, and their dysregulation contributes to cancer initiation, progression, metastasis, and therapy resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review connect Rho GTPase signaling to immunotherapy outcomes?",{"text":121,"@type":113},"It summarizes direct evidence linking Rho GTPases in tumor cells to immunotherapy responses and the indirect role of Rho GTPase signaling networks across immune cells, with a focus on ICIs and CAR-T therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354369,1790441818,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Biochemical Society Transactions (2026) 54 815–829 [https://doi.org/10.1042/BST20260485](https://doi.org/10.1042/BST20260485)  \nReview Article  \nImplications of Rho GTPase signaling in cancer immunotherapy  \n Mingjun Cai1,2 , Fukun Guo2 and Yi Zheng1,2  \n1 Graduate Program of Development, Stem Cells, and Regenerative Medicine, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, U.S.A. ;  \n2 Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, U.S.A.  \nCorrespondence: Yi Zheng ([yi.zheng@cchmc.org](yi.zheng@cchmc.org))  \nReceived: 06 March 2026  \nRevised: 28 May 2026  \nAccepted: 09 June 2026  \nVersion of Record published:  \n24 June 2026  \nCancer immunotherapy, including immune checkpoint inhibitors (ICIs) and  \nchimera-antigen receptor (CAR)-T cell therapy, has achieved substantial clinical success. However, response rates remain limited in many patients due to tumor-intrinsic immune evasion and immune cell dysfunction within the tumor microenvironment (TME) . Rho family small GTPases are key signaling regulators of cytoskeletal dynamics, intracellular trafficking, transcription, and metabolism in cancers. Emerging evidence implicates Rho GTPase signaling in mediating immunotherapy efficiency through its context-dependent functions. Individual Rho GTPases modulate immunotherapy responses in tumor cells and various immune cells through actomyosin-mediated chemotaxis, cell junctions, cell polarity, and gene/epigenetic networks, among other pathways. The present review summarizes both the direct evidence linking Rho GTPases in tumor cells to immunotherapy responses and the indirect role of the selective Rho GTPase signaling network in various immune cells, with a focus on the recent progress in understanding the molecular mechanisms and associated outcomes of the ICIs and CAR-T cell therapies. We highlight current knowledge gaps at the intersection of Rho GTPase biology and cancer immunology and discuss therapeutic implications, proposing that selective modulation of specific Rho GTPase signaling pathways in tumor or TME immune cells represents a promising strategy to improve immunotherapy efficiency.  \nIntroduction  \nCancer immunotherapy is a therapeutic strategy that boosts patients’immune systems to recognize and eliminate cancer cells [1] . It comprises a broad spectrum of approaches, including immune checkpoint inhibitors (ICIs), adoptive cell therapies (such as CAR-T, CAR-NK, and TCR-T cells), targeted antibodies (such as monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates), cancer therapeutic vaccines, and oncolytic viruses [2,3] . Among these, ICIs and CAR-T therapies have emerged in recent years as the most impactful FDA-approved immunotherapeutic strategies, with their high efficiency as evidenced by durable response, long-term survival benefit, and high objective response rate [4–8] . Although these therapies have seen remarkable clinical success, a substantial proportion of patients fail to respond [3], highlighting the need to identify mechanisms of tumor-immune interactions for improvement.  \nRho family GTPases are central regulators of cell cytoskeletal dynamics and polarity. Beyond these classical functions, Rho GTPases have emerged as critical signaling hubs that control vesicle trafficking, transcriptional regulation, and cell metabolism [9,10]. Dysregulation of Rho GTPase signaling is closely related to cancer, contributing to various aspects of cancer initiation, progression, metastasis, and therapy resistance [9] . Importantly, like the cases of oncogenic RAS, Rho GTPases and their downstream effectors are critical for immune cell development and TME modulation [11–13] . However, while there  \n© 2026 The Author(s) . This is an open access article published by Po","cbCailaqecCcvsBM","https://ap.wps.com/l/cbCailaqecCcvsBM","pdf",1516353,15,"English","# Introduction\n# Rho GTPase signaling in cancer and immunotherapy\n# Rho GTPase family members and immune-cell functions\n# Direct tumor-cell evidence and indirect immune-cell network roles\n# Therapeutic implications and future directions","[{\"question\":\"Why do some patients fail to respond to cancer immunotherapy?\",\"answer\":\"Response rates remain limited due to tumor-intrinsic immune evasion and immune cell dysfunction within the tumor microenvironment (TME).\"},{\"question\":\"What role do Rho family small GTPases play in cancer biology relevant to immunotherapy?\",\"answer\":\"Rho GTPases regulate cytoskeletal dynamics, intracellular trafficking, transcription, and metabolism, and their dysregulation contributes to cancer initiation, progression, metastasis, and therapy resistance.\"},{\"question\":\"How does the review connect Rho GTPase signaling to immunotherapy outcomes?\",\"answer\":\"It summarizes direct evidence linking Rho GTPases in tumor cells to immunotherapy responses and the indirect role of Rho GTPase signaling networks across immune cells, with a focus on ICIs and CAR-T therapies.\"}]","Implications of Rho GTPase signaling in cancer immunotherapy | PDF",1790110341,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63eee9a749fb0f64b0148e8871f75df8.webp",983,1301,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a465d8c9394ce52b5b75a16806ec0f9.webp",982,1299,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7c9da1c12563d938dff3c978797915b.webp",981,1298,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d524515f9eb976f4d41a1bfecdba2eb.webp",980,1297]